<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211809</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 00-0211PS*</org_study_id>
    <nct_id>NCT00211809</nct_id>
  </id_info>
  <brief_title>CBT as an Adjunct to SRIs in the Treatment of BDD</brief_title>
  <official_title>A Controlled Trial of Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research project is a controlled pilot study of the efficacy of cognitive-behavioral
      therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body
      dysmorphic disorder (BDD). This study assesses the efficacy of CBT in comparison to
      relaxation and stress management training (RSMT), an active control treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In total, 20 BDD patients aged 16 through 65 will participate. To be eligible they must meet
      DSM-IV criteria for BDD, have a score of 20 or greater on the BDD modification of the Yale
      Brown Obsessive-Compulsive Scale (BDD-YBOCS) and be on a stable, therapeutic does of an SRI
      (at least 12 weeks on the SRI with 8 weeks at a therapeutic dose: acceptable medications
      (therapeutic daily doses) are citalopram (40mg), clomipramine (150mg), fluoxetine (40mg),
      fluvoxamine (150mg), paroxetine (40mg), sertraline (50mg), and venlafaxine (150mg).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollment
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Dysmorphic Disorder Examination</measure>
    <time_frame>baseline and up to 16 weeks</time_frame>
    <description>Body Dysmorphic Disorder Examination - Self Reported (BDDE-SR) score - The BDDE-SR is a 30-item self-rating of BDD symptoms, with a more specific measure of body image dissatisfaction. Each item is rated 0 (no dissatisfaction to 6 (extreme dissatisfaction), with total score from 0 to 180.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yale Brown Obsessive Scale</measure>
    <time_frame>baseline and up to 16 weeks</time_frame>
    <description>Yale Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) - a 12-item semistructured clinician-rated instrument designed to rate severity of body dysmorphic disorder (BDD) symptoms during the past week. The score for each item ranges from 0 (no symptoms) to 4 (extreme symptoms). The BDD-YBOCS Obsession Subtotal score range is 0-20 and the BDD-YBOCS Compulsion Subtotal score range is 0-20. The BDD-YBOCS Insight/Avoidance Subtotal score range is 0-8. The total BDD-YBOCS score range is from 0 (not present or extremely mild) to 48 (severe). Each item is rated as a composite of all the patient's appearance related obsessions and compulsive behaviors independent of their content.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Dysmorphic Disorder Clinical Global Impressions Scale</measure>
    <time_frame>baseline and up to 16 weeks</time_frame>
    <description>The Clinical Global Impression-Improvement Scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brown Assessment of Beliefs Scale</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
    <description>The Brown Assessment of Beliefs Scale (BABS) rates the degree of conviction and insight patients have concerning their beliefs. The BABS consists of 7 items: the first 6 items are added to obtain the total BABS score. An additional item (ideas of reference) is not included in the total score. Scoring is from 0 (least severe) to 4 (most severe), with total score from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
    <description>The Beck Depression Inventory II (BDI-II) is a 21 item self-report inventory measuring the severity of depression. Individuals are asked to respond to each question based on a two-week time period. Scoring is from 0 (minimal) to 3 (severe), with total score from 0-63. Higher total scores indicate more severe depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory</measure>
    <time_frame>Baseline and up to 16 weeks</time_frame>
    <description>The Beck Anxiety Inventory (BAI) is a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Body Dysmorphic Disorder</condition>
  <arm_group>
    <arm_group_label>Body dysmorphic disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with body dysmorphic disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>standard psychiatric evaluation</description>
    <arm_group_label>Body dysmorphic disorder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.</description>
    <arm_group_label>Body dysmorphic disorder</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 16-65

          -  A diagnosis of DSM-IV BDD or its delusional variant (delusional disorder, somatic
             type)

          -  Ability to communicate meaningfully with the investigators

          -  Competent to provide written consent, if over 18 years old, or competent to provide
             written assent, if 16-17 years, 11 months

          -  Parental consent, if under 18 years old

          -  For phase two: must be on a stable therapeutic dose of one of the following SRI
             medications for at least 8 weeks: fluoxetine, fluvoxamine, venlafaxine, clomipramine,
             paroxetine, citalopram, or sertraline.

        Exclusion Criteria:

          -  current or lifetime diagnosis of any DSM_IV psychotic disorder not attributable to
             delusional BDD, current or lifetime diagnosis of DSM-IV bipolar disorder,

          -  current or recent (within 2 months of study entry) DSM-IV alcohol or substance
             dependence or abuse,

          -  recent suicide attempt, or suicidal ideation that warrants consideration of
             hospitalization,

          -  need for inpatient or partial hospital treatment,

          -  use of any medication prescribed for the treatment of BDD other than SRIs, including
             tricyclic antidepressants, buspirone, or neuroleptics,

          -  presence of any significant and/or unstable medical condition,

          -  females who are pregnant or breast-feeding, or who are sexually active and not using
             adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hollander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Allen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Baker BR, Greenberg JL, Hollander E. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008 Feb;13(2):138-44.</citation>
    <PMID>18227745</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Body Dysmorphic Disorder</keyword>
  <keyword>SRIs</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Dysmorphic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by advertising and other media and by referral from outside clinicians.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Body Dysmorphic Disorder</title>
          <description>Participants with body dysmorphic disorder
Standard Psychiatric Evaluation
Venlafaxine: start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>side effects</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Body Dysmorphic Disorder</title>
          <description>Participants with body dysmorphic disorder</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SSRI history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>SSRI naive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>prior failed SSRI trials</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Dysmorphic Disorder Examination</title>
        <description>Body Dysmorphic Disorder Examination - Self Reported (BDDE-SR) score - The BDDE-SR is a 30-item self-rating of BDD symptoms, with a more specific measure of body image dissatisfaction. Each item is rated 0 (no dissatisfaction to 6 (extreme dissatisfaction), with total score from 0 to 180.</description>
        <time_frame>baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Participants with Body Dysmorphic Disorder at baseline</description>
          </group>
          <group group_id="O2">
            <title>Endpoint</title>
            <description>Participants with Body Dysmorphic Disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Dysmorphic Disorder Examination</title>
          <description>Body Dysmorphic Disorder Examination - Self Reported (BDDE-SR) score - The BDDE-SR is a 30-item self-rating of BDD symptoms, with a more specific measure of body image dissatisfaction. Each item is rated 0 (no dissatisfaction to 6 (extreme dissatisfaction), with total score from 0 to 180.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.91" spread="27.41"/>
                    <measurement group_id="O2" value="107.73" spread="39.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Yale Brown Obsessive Scale</title>
        <description>Yale Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) - a 12-item semistructured clinician-rated instrument designed to rate severity of body dysmorphic disorder (BDD) symptoms during the past week. The score for each item ranges from 0 (no symptoms) to 4 (extreme symptoms). The BDD-YBOCS Obsession Subtotal score range is 0-20 and the BDD-YBOCS Compulsion Subtotal score range is 0-20. The BDD-YBOCS Insight/Avoidance Subtotal score range is 0-8. The total BDD-YBOCS score range is from 0 (not present or extremely mild) to 48 (severe). Each item is rated as a composite of all the patient's appearance related obsessions and compulsive behaviors independent of their content.</description>
        <time_frame>baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Participants with Body Dysmorphic Disorder at baseline</description>
          </group>
          <group group_id="O2">
            <title>Endpoint</title>
            <description>Participants with Body Dysmorphic Disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Yale Brown Obsessive Scale</title>
          <description>Yale Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS) - a 12-item semistructured clinician-rated instrument designed to rate severity of body dysmorphic disorder (BDD) symptoms during the past week. The score for each item ranges from 0 (no symptoms) to 4 (extreme symptoms). The BDD-YBOCS Obsession Subtotal score range is 0-20 and the BDD-YBOCS Compulsion Subtotal score range is 0-20. The BDD-YBOCS Insight/Avoidance Subtotal score range is 0-8. The total BDD-YBOCS score range is from 0 (not present or extremely mild) to 48 (severe). Each item is rated as a composite of all the patient's appearance related obsessions and compulsive behaviors independent of their content.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Psychiatrist's Ratings for Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.64" spread="5.09"/>
                    <measurement group_id="O2" value="26.55" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatrist's Ratings for Obsessions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.73" spread="2.20"/>
                    <measurement group_id="O2" value="11.45" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatrist's Ratings for Compulsions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.82" spread="1.20"/>
                    <measurement group_id="O2" value="11.55" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist's Ratings for Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.91" spread="4.21"/>
                    <measurement group_id="O2" value="28.27" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist's Ratings for Obsessions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.45" spread="4.57"/>
                    <measurement group_id="O2" value="12.09" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist's Ratings for Compulsions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.09" spread="2.30"/>
                    <measurement group_id="O2" value="12.18" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Dysmorphic Disorder Clinical Global Impressions Scale</title>
        <description>The Clinical Global Impression-Improvement Scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
        <time_frame>baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Body Dysmorphic Disorder</title>
            <description>Participants with body dysmorphic disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Body Dysmorphic Disorder Clinical Global Impressions Scale</title>
          <description>The Clinical Global Impression-Improvement Scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Psychiatrist's Ratings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist's Ratings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brown Assessment of Beliefs Scale</title>
        <description>The Brown Assessment of Beliefs Scale (BABS) rates the degree of conviction and insight patients have concerning their beliefs. The BABS consists of 7 items: the first 6 items are added to obtain the total BABS score. An additional item (ideas of reference) is not included in the total score. Scoring is from 0 (least severe) to 4 (most severe), with total score from 0 to 24.</description>
        <time_frame>Baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Participants with Body Dysmorphic Disorder at baseline</description>
          </group>
          <group group_id="O2">
            <title>Endpoint</title>
            <description>Participants with Body Dysmorphic Disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Brown Assessment of Beliefs Scale</title>
          <description>The Brown Assessment of Beliefs Scale (BABS) rates the degree of conviction and insight patients have concerning their beliefs. The BABS consists of 7 items: the first 6 items are added to obtain the total BABS score. An additional item (ideas of reference) is not included in the total score. Scoring is from 0 (least severe) to 4 (most severe), with total score from 0 to 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Psychiatrist's Ratings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.82" spread="5.19"/>
                    <measurement group_id="O2" value="16.91" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychologist's Ratings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.91" spread="6.47"/>
                    <measurement group_id="O2" value="14.82" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory II</title>
        <description>The Beck Depression Inventory II (BDI-II) is a 21 item self-report inventory measuring the severity of depression. Individuals are asked to respond to each question based on a two-week time period. Scoring is from 0 (minimal) to 3 (severe), with total score from 0-63. Higher total scores indicate more severe depressive symptoms.</description>
        <time_frame>Baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Participants with Body Dysmorphic Disorder at baseline</description>
          </group>
          <group group_id="O2">
            <title>Endpoint</title>
            <description>Participants with Body Dysmorphic Disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory II</title>
          <description>The Beck Depression Inventory II (BDI-II) is a 21 item self-report inventory measuring the severity of depression. Individuals are asked to respond to each question based on a two-week time period. Scoring is from 0 (minimal) to 3 (severe), with total score from 0-63. Higher total scores indicate more severe depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.77" spread="11.49"/>
                    <measurement group_id="O2" value="22.18" spread="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Anxiety Inventory</title>
        <description>The Beck Anxiety Inventory (BAI) is a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms.</description>
        <time_frame>Baseline and up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Participants with Body Dysmorphic Disorder at baseline</description>
          </group>
          <group group_id="O2">
            <title>Endpoint</title>
            <description>Participants with Body Dysmorphic Disorder after Venlafaxine treatment up to 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Anxiety Inventory</title>
          <description>The Beck Anxiety Inventory (BAI) is a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.90" spread="8.23"/>
                    <measurement group_id="O2" value="12.55" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Body Dysmorphic Disorder</title>
          <description>Participants with body dysmorphic disorder</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitations of this study are the small sample size, the open-label design, and the primarily female sample.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Andrea Allen</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-3176</phone>
      <email>andrea.allen@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

